Compare Capital One Financial Corp. (COF) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capital One Financial Corp. vs DexCom, Inc. — how do they compare? Capital One Financial Corp. trades at $219.77 (market cap $134.45B), while DexCom, Inc. trades at $89.07 (market cap $33.79B). The key difference: Capital One Financial Corp. is far larger — about 4× DexCom, Inc.'s market cap, and Capital One Financial Corp. pays a 1.46% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| COF | DXCM | |
|---|---|---|
Market Cap | $134.45B | $33.79B |
Sector | Financials | Health |
52-Week High | $257.94 | $89.53 |
52-Week Low | $176.10 | $54.84 |
Dividend Yield | 1.46% | — |
Enterprise Value | — | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $218.97, up 0.56% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $251.60. Recent Q2 2026 earnings beat expectations with EPS of $5.81, while revenue growth accelerated to $53.43B in 2025. The Discover integration is on track, targeting $2.5B in synergies by late 2027, supporting double-digit EPS growth projections.
The outlook is positive, driven by strong card growth, technology advantages, and merger synergies, but risks include integration execution, credit loss provisions, and macroeconomic sensitivity. With a P/E of 12.07 and 63% analyst buy ratings, the stock offers value if Discover benefits materialize as planned.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
